Skip to main content
BUKWANG PHARMACEUTICAL IND CO.,LTD logo

BUKWANG PHARMACEUTICAL IND CO.,LTD - Investor Relations & Filings

Listed IPO Aug 1988
Ticker · 003000 ISIN · KR7003000007 KO Manufacturing
Open in API
Filings indexed 327 across all filing types
Latest filing 2026-02-23 Proxy Solicitation & In…
Country KR South Korea
Listing KO 003000 · 1 venue

About BUKWANG PHARMACEUTICAL IND CO.,LTD

https://www.bukwang.co.kr/en/

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Bukwang Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, dividend proposals, and board compensation) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and the matters to be voted upon.
2026-02-23 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is an official announcement from Bukwang Pharmaceutical regarding the decision to pay a cash dividend. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-23 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms under the Fair Transactions in Subcontracting Act (Article 13-3). It is a specific, structured regulatory filing required by law in South Korea for corporate transparency. Since it does not fit into categories like financial reports, earnings releases, or shareholder communications, it falls under the 'Regulatory Filings' category.
2026-02-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Bukwang Pharm) announcing a significant change in financial results (30% or more change in revenue or profit structure). This is a standard preliminary earnings announcement (often referred to as '잠정실적' in Korean regulatory filings) that provides key financial highlights for the fiscal year. It is not a full annual report (10-K) but rather an initial release of financial performance data, which fits the 'Earnings Release' (ER) category.
2026-02-09 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 98% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling of an upcoming Investor Relations (IR) event. It provides the date, time, and purpose of the meeting but does not contain the actual presentation materials or financial results themselves. According to the 'Menu vs Meal' rule, an announcement of a report or event is classified as a Report Publication Announcement (RPA).
2026-02-02 Korean
투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from Bukwang Pharmaceutical announcing its selection as the final acquirer of Korea Union Pharm, which is currently under rehabilitation proceedings. The content details the acquisition method (third-party capital increase), the acquisition amount (30 billion KRW), and the status of the M&A process. This falls squarely under M&A activity (TAR).
2026-01-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.